Optimal conditions for lentiviral transduction of engrafting human CD34 + cells

Gene Therapy

Volumn 18, Issue 11, 2011, Pages 1078-1086

  Uchida, N ^a   Hsieh, M M ^a   Hayakawa, J ^a   Madison, C ^a   Washington, K N ^a   Tisdale, J F ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

hematopoietic stem cell; human CD34 + cell; humanized xenograft mouse; lentiviral vector; transduction efficiency

Indexed keywords

CD34 ANTIGEN; FLT3 LIGAND; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; STEM CELL FACTOR; THROMBOPOIETIN;

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; ENGRAFTMENT; ENRICHMENT CULTURE; EX VIVO STUDY; GENE EXPRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SERUM; STEM CELL GENE THERAPY; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTIGENS, CD34; CULTURE MEDIA, SERUM-FREE; FMS-LIKE TYROSINE KINASE 3; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERLEUKIN-3; LENTIVIRUS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MODELS, ANIMAL; STEM CELL FACTOR; THROMBOPOIETIN; TRANSDUCTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS;

BOVINAE; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 80855131580     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.63     Document Type: Article

References (47)

1. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346: 1185-1193. (Pubitemid 34984579)
2. Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009; 360: 447-458.
3. May C, Rivella S, Callegari J, Heller G, Gaensler KM, Luzzatto L et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature 2000; 406: 82-86. (Pubitemid 30460215)
4. Imren S, Payen E, Westerman KA, Pawliuk R, Fabry ME, Eaves CJ et al. Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells. Proc Natl Acad Sci USA 2002; 99: 14380-14385. (Pubitemid 35257680)
5. Levasseur DN, Ryan TM, Pawlik KM, Townes TM. Correction of a mouse model of sickle cell disease: lentiviral/antisickling beta-globin gene transduction of unmobilized, purified hematopoietic stem cells. Blood 2003; 102: 4312-4319. (Pubitemid 37494089)
6. Pawliuk R, Westerman KA, Fabry ME, Payen E, Tighe R, Bouhassira EE et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 2001; 294: 2368-2371. (Pubitemid 33140563)
7. Persons DA, Allay ER, Sabatino DE, Kelly P, Bodine DM, Nienhuis AW. Functional requirements for phenotypic correction of murine beta-thalassemia: implications for human gene therapy. Blood 2001; 97: 3275-3282.
8. Rivella S, May C, Chadburn A, Riviere I, Sadelain M. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. Blood 2003; 101: 2932-2939. (Pubitemid 36857977)
9. Slaets H, Hendriks JJ, Van den Haute C, Coun F, Baekelandt V, Stinissen P et al. CNStargeted LIF expression improves therapeutic efficacy and limits autoimmune-mediated demyelination in a model of multiple sclerosis. Mol Ther 2010; 18: 684-691.
10. Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010; 467: 318-322.
11. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol 2007; 7: 118-130. (Pubitemid 46174859)
12. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002; 100: 3175-3182. (Pubitemid 35217065)
13. Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood 2005; 106: 1565-1573. (Pubitemid 41208567)
14. Watanabe S, Terashima K, Ohta S, Horibata S, Yajima M, Shiozawa Y et al. Hematopoietic stem cell-engrafted NOD/SCID/IL2Rgamma null mice develop human lymphoid systems and induce long-lasting HIV-1 infection with specific humoral immune responses. Blood 2007; 109: 212-218. (Pubitemid 46070123)
15. Roesler J, Brenner S, Bukovsky AA, Whiting-Theobald N, Dull T, Kelly M et al. Thirdgeneration, self-inactivating gp91(phox) lentivector corrects the oxidase defect in NOD/SCID mouse-repopulating peripheral blood-mobilized CD34+ cells from patients with X-linked chronic granulomatous disease. Blood 2002; 100: 4381-4390. (Pubitemid 35429676)
16. Piacibello W, Bruno S, Sanavio F, Droetto S, Gunetti M, Ailles L et al. Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice. Nonobese diabetic/severe combined immunodeficient. Blood 2002; 100: 4391-4400. (Pubitemid 35429677)
17. Naumann N, De Ravin SS, Choi U, Moayeri M, Whiting-Theobald N, Linton GF et al. Simian immunodeficiency virus lentivector corrects human X-linked chronic granulo-matous disease in the NOD/SCID mouse xenograft. Gene Therapy 2007; 14: 1513-1524. (Pubitemid 47570710)
18. Miyoshi H, Smith KA, Mosier DE, Verma IM, Torbett BE. Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 1999; 283: 682-686.
19. Sellers SE, Tisdale JF, Agricola BA, Donahue RE, Dunbar CE. The presence of the carboxy-terminal fragment of fibronectin allows maintenance of non-human primate long-term hematopoietic repopulating cells during extended ex vivo culture and transduction. Exp Hematol 2004; 32: 163-170. (Pubitemid 38177642)
20. Tisdale JF, Hanazono Y, Sellers SE, Agricola BA, Metzger ME, Donahue RE et al. Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability. Blood 1998; 92: 1131-1141. (Pubitemid 28369025)
21. Kiem HP, Andrews RG, Morris J, Peterson L, Heyward S, Allen JM et al. Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor. Blood 1998; 92: 1878-1886. (Pubitemid 28446676)
22. Williams DA, Rios M, Stephens C, Patel VP. Fibronectin and VLA-4 in haematopoietic stem cell-microenvironment interactions. Nature 1991; 352: 438-441. (Pubitemid 21896743)
23. Dunbar CE. Gene transfer to hematopoietic stem cells: implications for gene therapy of human disease. Annu Rev Med 1996; 47: 11-20. (Pubitemid 26138868)
24. Bukrinsky MI, Haggerty S, Dempsey MP, Sharova N, Adzhubel A, Spitz L et al. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 1993; 365: 666-669. (Pubitemid 23350541)
25. Abonour R, Williams DA, Einhorn L, Hall KM, Chen J, Coffman J et al. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med 2000; 6: 652-658. (Pubitemid 30398788)
26. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669-672. (Pubitemid 30241569)
27. Kluge KA, Bonifacino AC, Sellers S, Agricola BA, Donahue RE, Dunbar CE. Retroviral transduction and engraftment ability of primate hematopoietic progenitor and stem cells transduced under serum-free versus serum-containing conditions. Mol Ther 2002; 5: 316-322. (Pubitemid 34211227)
28. Millington M, Arndt A, Boyd M, Applegate T, Shen S. Towards a clinically relevant lentiviral transduction protocol for primary human CD34 hematopoietic stem/progenitor cells. PLoS One 2009; 4: e6461.
29. Selvaggi TA, Walker RE, Fleisher TA. Development of antibodies to fetal calf serum with arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions. Blood 1997; 89: 776-779. (Pubitemid 27121269)
30. Yonemura Y, Ku H, Hirayama F, Souza LM, Ogawa M. Interleukin 3 or interleukin 1 abrogates the reconstituting ability of hematopoietic stem cells. Proc Natl Acad Sci USA 1996; 93: 4040-4044. (Pubitemid 26144242)
31. Bodine DM, Karlsson S, Nienhuis AW. Combination of interleukins 3 and 6 preserves stem cell function in culture and enhances retrovirus-mediated gene transfer into hematopoietic stem cells. Proc Natl Acad Sci USA 1989; 86: 8897-8901. (Pubitemid 20010332)
32. Piacibello W, Gammaitoni L, Bruno S, Gunetti M, Fagioli F, Cavalloni G et al. Negative influence of IL3 on the expansion of human cord blood in vivo long-term repopulating stem cells. J Hematother Stem Cell Res 2000; 9: 945-956. (Pubitemid 32110296)
33. Zandstra PW, Conneally E, Petzer AL, Piret JM, Eaves CJ. Cytokine manipulation of primitive human hematopoietic cell self-renewal. Proc Natl Acad Sci USA 1997; 94: 4698-4703.
34. Dunbar CE, Takatoku M, Donahue RE. The impact of ex vivo cytokine stimulation on engraftment of primitive hematopoietic cells in a non-human primate model. Ann NY Acad Sci 2001; 938: 236-244; discussion 244-245.
35. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection.Mol Cell Biol 1990; 10: 4239-4242.
36. Karlsson S. Treatment of genetic defects in hematopoietic cell function by gene transfer. Blood 1991; 78: 2481-2492.
37. Vigna E, Naldini L. Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med 2000; 2: 308-316.
38. Geronimi F, Richard E, Redonnet-Vernhet I, Lamrissi-Garcia I, Lalanne M, Ged C et al. Highly efficient lentiviral gene transfer in CD34+ and CD34+/38-/lin-cells from mobilized peripheral blood after cytokine prestimulation. Stem Cells 2003; 21: 472-480. (Pubitemid 36793489)
39. Higashimoto T, Grassman E, Cancelas JA, Malik P. Small but powerful, predicting the outcome of gene therapy trial using NSG Mice. Mol Ther 2010; 18 (Suppl 1): 203 (abstract 526).
40. Peters SO, Kittler EL, Ramshaw HS, Quesenberry PJ. Murine marrow cells expanded in culture with IL-3, IL-6, IL-11, and SCF acquire an engraftment defect in normal hosts. Exp Hematol 1995; 23: 461-469.
41. Herrera C, Sanchez J, Torres A, Bellido C, Rueda A, Alvarez MA. Early-acting cytokinedriven ex vivo expansion of mobilized peripheral blood CD34+ cells generates postmitotic offspring with preserved engraftment ability in non-obese diabetic/severe combined immunodeficient mice. Br J Haematol 2001; 114: 920-930. (Pubitemid 32953756)
42. Malim MH. APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond Ser B 2009; 364: 675-687.
43. Luban J. Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type infection. J Virol 2007; 81: 1054-1061. (Pubitemid 46170755)
44. Hayakawa J, Joyal EG, Gildner JF, Washington KN, Phang OA, Uchida N et al. 5% dimethyl sulfoxide (DMSO) and pentastarch improves cryopreservation of cord blood cells over 10% DMSO. Transfusion 2010; 50: 2158-2166.
45. Hanawa H, Kelly PF, Nathwani AC, Persons DA, Vandergriff JA, Hargrove P et al. Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood. Mol Ther 2002; 5: 242-251. (Pubitemid 34211219)
46. Uchida N, Hanawa H, Dan K, Inokuchi K, Shimada T. Leukemogenesis of b2a2-type p210 BCR/ABL in a bone marrow transplantation mouse model using a lentiviral vector. J Nippon Med Sch 2009; 76: 134-147.
47. Uchida N, Washington KN, Hayakawa J, Hsieh MM, Bonifacino AC, Krouse AE et al. Development of an HIV1-based lentiviral vector that allows efficient transduction of both human and rhesus blood cells. J Virol 2009; 83: 9854-9862.